search button

Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome

  • Authors:
    • Faruk Tas
    • Elif Bilgin
    • Senem Karabulut
    • Didem Tastekin
    • Derya Duranyildiz

  • View Affiliations

  • Published online on: February 2, 2016     https://doi.org/10.3892/mco.2016.759
  • Pages: 655-659
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Fibronectin is an important component of the extracellular matrix and serves a role in the pathogenesis of multiple malignancies. The expression of fibronectin also affects the outcome for patients with cancer. The objective of the present study was to determine the clinical significance of the serum fibronectin levels in patients with gastric cancer. A total of 63 patients with a pathologically confirmed diagnosis of gastric cancer were enrolled into the present study. Serum fibronectin concentrations were determined by the solid‑phase sandwich enzyme‑linked immunosorbent assay method. Age and sex matched healthy controls (n=30) were included in the analysis. The median age at diagnosis was 62 years (range 28‑82 years). The baseline serum fibronectin levels of the patients with gastric cancer were significantly higher compared with those in the control group (median values, 606, vs. 193 ng/ml; P<0.001). The known clinical variables, including the age of the patient, gender, site of lesion, histology, histological grade, stage of disease and serum tumor markers, including lactate dehydrogenase, carcinoembryonic antigen and cancer antigen 19.9, were not found to be correlated with serum fibronectin concentrations (P>0.05). In addition, no correlation was observed in serum fibronectin level and response to chemotherapy (P=0.12). Serum fibronectin concentration demonstrated no prognostic role on survival (P=0.43). In conclusion, the serum levels of fibronectin may have a good diagnostic marker in patients with gastric cancer. However, its predictive and prognostic values remain to be elucidated.
View Figures
View References

Related Articles

Journal Cover

April-2016
Volume 4 Issue 4

Print ISSN: 2049-9450
Online ISSN:2049-9469

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 1.4
  • Ranked
    (total number of cites)
  • CiteScore: 2.8
  • CiteScore Rank: Q3: #250/404 Oncology
  • Source Normalized Impact per Paper (SNIP): 0.55
  • SCImago Journal Rank (SJR): 0.446
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Tas F, Bilgin E, Karabulut S, Tastekin D and Duranyildiz D: Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome. Mol Clin Oncol 4: 655-659, 2016.
APA
Tas, F., Bilgin, E., Karabulut, S., Tastekin, D., & Duranyildiz, D. (2016). Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome. Molecular and Clinical Oncology, 4, 655-659. https://doi.org/10.3892/mco.2016.759
MLA
Tas, F., Bilgin, E., Karabulut, S., Tastekin, D., Duranyildiz, D."Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome". Molecular and Clinical Oncology 4.4 (2016): 655-659.
Chicago
Tas, F., Bilgin, E., Karabulut, S., Tastekin, D., Duranyildiz, D."Levels of serum fibronectin as a biomarker in gastric cancer patients: Correlation with clinical diagnosis and outcome". Molecular and Clinical Oncology 4, no. 4 (2016): 655-659. https://doi.org/10.3892/mco.2016.759